**ValuHealth Acetaminophen Recall: Labeling Error Leads to Nationwide Action**
:max_bytes(150000):strip_icc():format(jpeg)/acetaminophen-110326-bc22be173d414b4481cf7fb18118ba00.jpg)
Prodose, Inc., the parent company of ValuHealth, has initiated a voluntary recall of its ValuHealth Extra Strength Pain Relief Acetaminophen, affecting over 100,000 bottles across the country. The recall was announced by the Food and Drug Administration (FDA) on October 14, 2023, in response to a significant labeling error.
The issue arose when the inner label of the product incorrectly classified the medication as a PM formula, despite the outer label properly identifying it as ValuHealth Extra Strength Pain Relief Acetaminophen 500 mg. Such a mix-up could lead to confusion among consumers, particularly since PM formulas typically contain ingredients designed to aid sleep.
The affected ValuHealth product is primarily sold at Dollar Tree locations, making the recall particularly noteworthy for budget-conscious shoppers who rely on the affordability of such retailers. According to the FDA, the specific lot number associated with the recalled product is P260252, with a Universal Product Code (UPC) of 850026889000. The affected bottles had an expiration date of April 30, 2029.
Despite the scale of the recall, the FDA classified this incident as a Class III recall. This designation indicates that the agency believes the likelihood of the recalled product causing adverse health effects is minimal. According to the FDA, “use of or exposure to a violative Class III product is not likely to cause adverse health consequences.”
In response to the recall, ValuHealth has encouraged customers to examine their purchases. They advise any individuals who may have purchased the affected product to return it to the place of purchase for a full refund. Customers who require further information are encouraged to reach out directly to the company or check the FDA’s website for updates.
Interestingly, this recall follows another significant incident involving acetaminophen products. In mid-September, Aurobindo Pharma USA Inc., another manufacturer, recalled over 100,000 bottles of Amazon Basic Care Extra Strength Pain Relief due to reports of tablet discoloration. Though the discoloration raised concerns, it was determined that the safety and efficacy of the medication remained intact.
The earlier Aurobindo recall encompassed various bottle sizes, including 200-count, 500-count, and 1,000-count formats. The total number of bottles recalled in that instance included 14,640 from the 200-count lot, 90,456 from the 500-count, and 7,836 from the 1,000-count lot. As with the ValuHealth recall, there were no reports of adverse effects related to the discoloration issue.
These recent recalls highlight ongoing concerns about product safety and labelling accuracy, especially for over-the-counter medications. Given the prevalence of acetaminophen in household medicine cabinets, it is crucial for consumers to remain vigilant and informed about the products they purchase.
As always, maintaining clear and accurate labelling on pharmaceuticals is vital in ensuring consumer safety. The FDA’s oversight plays an essential role in identifying potential issues and facilitating recalls to protect the public from confusing or potentially harmful products.
For anyone looking to stay informed about further developments regarding this recall or any future safety alerts, signing up for news updates from reliable sources can be a prudent step. Staying aware of product recalls not only helps consumers protect themselves but also fosters greater accountability within the pharmaceutical industry.
About the Author
